IDHIFA® For Relapsed / Refractory Acute Myeloid Leukemia
Learn more about IDHIFA® (enasidenib) for patients with relapsed/refractory acute myeloid leukemia (AML) with an IDH2 mutation. See safety info and BOXED WARNING on differentiation syndrome.
About IDHIFA® and How It Works | Patient Site
What is IDHIFA ® and what is an IDH2 mutation? IDHIFA ® is an oral prescription medicine used to treat people with AML with an IDH2 mutation whose disease has come back or has not improved after previous treatment (s). It is not known if IDHIFA ® is safe and effective in children.
IDHIFA® is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s).
¿Qué es IDHIFA® (enasidenib)? IDHIFA® es un medicamento con receta que se utiliza para tratar a personas con leucemia mieloide aguda (LMA) con una mutación en el gen isocitrato deshidrogenasa 2 (IDH2) cuya enfermedad ha reaparecido o no ha mejorado después de un tratamiento(s) previo(s). Se desconoce si IDHIFA® es seguro y eficaz en niños.
IDHIFA® (enasidenib) es un medicamento con receta que se usa para tratar a personas con leucemia mieloide aguda (LMA) con una mutación de la isocitrato dehidrogenasa-2 (IDH2) cuya enfermedad ha regresado o no ha mejorado después de tratamiento(s) previo(s).
IDHIFA® (enasidenib) is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s).
¿Qué es IDHIFA? IDHIFA® (enasidenib) es un medicamento de venta con prescripción utilizado para el tratamiento de la leucemia mielógena aguda (AML, por sus siglas en inglés) en personas que tienen una mutación en la isocitrato deshidrogenasa 2 (IDH2), cuyo cáncer ha reaparecido o no ha mejorado después de haber recibido tratamiento previo.
IDHIFA® (enasidenib) is a prescription medicine used to treat people with acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation whose disease has come back or has not improved after previous treatment(s).
IDHIFA®es un medicamento recetado que se usa para tratar a personas con leucemia mieloide aguda (LMA) con una mutación de isocitrato deshidrogenasa-2 (isoocitrate dehydrogenase-2, IDH2) cuya enfermedad ha reaparecido o no ha mejorado después de tratamiento(s) previos.
As a caregiver, you have the important and often challenging role of providing emotional and physical support for someone with relapsed/refractory AML. Whether you are caring for a partner, spouse, family member, or friend, this guide will provide advice and information about caregiving, including the importance of caring for yourself.